AOXG Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume2.07K
Average Volume (3M)102.10K
Market Cap
$800.54K
Enterprise Value$383.90K
Total Cash (Recent Filing)$23.83K
Total Debt (Recent Filing)$102.87K
Price to Earnings (P/E)―
Beta-0.99
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding381,209,200
10 Day Avg. Volume12,736
30 Day Avg. Volume102,100
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue19.90
Enterprise Value/Gross Profit22.59
Enterprise Value/Ebitda-28.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AOXG FAQ
What was Aoxing Pharmaceutical Company Inc’s price range in the past 12 months?
Aoxing Pharmaceutical Company Inc lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Aoxing Pharmaceutical Company Inc’s market cap?
Aoxing Pharmaceutical Company Inc’s market cap is $800.54K.
When is Aoxing Pharmaceutical Company Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aoxing Pharmaceutical Company Inc’s earnings last quarter?
Aoxing Pharmaceutical Company Inc released its earnings results on May 15, 2017. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.
Is Aoxing Pharmaceutical Company Inc overvalued?
According to Wall Street analysts Aoxing Pharmaceutical Company Inc’s price is currently Overvalued.
Does Aoxing Pharmaceutical Company Inc pay dividends?
Aoxing Pharmaceutical Company Inc does not currently pay dividends.
What is Aoxing Pharmaceutical Company Inc’s EPS estimate?
Aoxing Pharmaceutical Company Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aoxing Pharmaceutical Company Inc have?
Aoxing Pharmaceutical Company Inc has 381,209,200 shares outstanding.
What happened to Aoxing Pharmaceutical Company Inc’s price movement after its last earnings report?
Aoxing Pharmaceutical Company Inc reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Aoxing Pharmaceutical Company Inc?
Currently, no hedge funds are holding shares in AOXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aoxing Pharmaceutical Company Inc
Aoxing Pharmaceutical Company, Inc. is a specialized drug manufacturer primarily operating within the People's Republic of China. The company dedicates itself to the research, development, production, and distribution of pharmaceutical products, with a strong emphasis on narcotics, pain management solutions, and addiction treatments. Its current product portfolio includes Zhongtong'an, a capsule derived from herbal extracts used for relieving oral and dental discomfort; Yiqi Qiangshen Granule, an over-the-counter herbal preparation designed to invigorate qi, strengthen the body, and improve blood flow by clearing meridian blockages; and Tilidine hydrochloride. The latter is an oral synthetic narcotic analgesic tablet, available in 50mg or 100mg doses, prescribed for the alleviation of acute, moderate to severe pain, as well as chronic pain associated with cancer. Aoxing also boasts several promising products in its development pipeline. These include Oxycodone and Acetaminophen tablets and capsules, which have successfully completed clinical trials for both acute and chronic pain management. Another is Buprenorphine/Naloxone, a sublingual combination tablet that has finished Phase II clinical trials as a treatment for opioid dependence. Furthermore, a Tilidine/Naloxone compound capsule is currently undergoing Phase II clinical trials, targeting acute and chronic pain. Initially known as China Aoxing Pharmaceutical Company, Inc., the firm rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010. Its corporate headquarters are situated in Shijiazhuang, China.
Technical Analysis
Bio Green Med Solution
―
SCYNEXIS
―
Biofrontera
―
Hong Kong Pharma Digital Technology Holdings Ltd.
―
Nasus Pharma Ltd.
―
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors